Products - Cervical cancer | Topic | NICE

Showing 4 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2026
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC